Cover Image
市場調查報告書

樹狀細胞及CAR-T治療

Dendritic Cell and CAR-T Therapies, 2014 - 2024

出版商 ROOTS ANALYSIS 商品編碼 319611
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
樹狀細胞及CAR-T治療 Dendritic Cell and CAR-T Therapies, 2014 - 2024
出版日期: 2014年11月20日 內容資訊: 英文 187 Pages
簡介

藥物開發業者日益關注活用人體免疫系統或其構成要素來抗癌的免疫療法。尤其是包含了樹狀細胞治療(DCT)與嵌合抗原受體T細胞治療(CAR-T)等基於細胞的免疫治療法更是眾人注目。

本報告以樹狀細胞治療及嵌合抗原受體T細胞治療這2種基於全細胞之免疫療法為焦點,彙整現狀與臨床/前臨床研究趨勢,技術開發,相關利益者的機會等資料。

第1章 序論

第2章 摘要整理

第3章 癌症治療和腫瘤免疫學

  • 本章概要
  • 癌症治療的4個柱子
  • 免疫治療
  • 腫瘤免疫學
  • 癌症免疫治療的分類

第4章 目前市場趨勢

  • 範圍與觀察
  • 樹狀細胞治療在2007年登場
  • 基於全細胞的免疫治療:臨床及前臨床開發平台
  • DCT和CAR-T:比較
  • DCT和CAR-T:創業投資公司的資金
  • 未來發展預測

第5章 樹狀細胞治療(DCT):主要的分子和未來發展預測

  • 簡介
  • 市場上2個已通過核准產品
  • 開發平台的複數新分子
  • PROVENGE
  • CreaVax-RCC
  • AGS-003
  • DCVax-L
  • DCVAC/PCa
  • Eltrapuldencel-T
  • DCT整體市場:2014∼2024年
  • 技術發展
  • DCT:今後預測

第6章 嵌合抗原受體T細胞治療

  • 簡介
  • 嵌合抗原受體結構
  • CTL019
  • JCAR
  • KTE-C19
  • CD19 CAR
  • EFGRvIII CAR
  • ANTI-GD2 CAR
  • CAR-T整體市場
  • 技術發展
  • DCT:今後預測

第7章 企業簡介

  • 概要
  • Dendreon Corporation
  • JW CreaGene
  • Northwest Biotherapeutics
  • Argos Therapeutics
  • NeoStem
  • SOTIO
  • Novartis
  • Juno Therapeutics
  • Kite Pharma巷
  • TaKaRa BIO株式會社
  • 其他

第8章 採訪原稿

第9章 結論

第10章 附錄1

第11章 附錄2

圖表

目錄
Product Code: RA10027

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeutics including cell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).

DCT makes use of autologous or allogenic Antigen Presenting Cells (APCs) to stimulate the immune system to recognise and act against the tumors. In April 2010, the FDA approval of Sipuleucel-T (PROVENGE, manufactured by Dendreon Corporation), a dendritic cell vaccine, gave a push to the concept of DCT. However, the vaccine hasn't been able to meet the high expectations. Despite this, the overall DCT outlook is promising; late stage development vaccines such as AGS-003, DCVax-L, DCVAC/PCa and Eltrapuldencel-T are likely to carry forward the baton.

With the similar aim to stimulate the body's immune system, CAR-T uses the patient's autologous effector T-cells, modifying it with a synthetic receptor enabling it to increase the tumor specific immune response. This therapy is expected to first enter market with the launch of CTL019 by Novartis in the next few years. In recent trials, CTL019 has shown complete remission in children with advanced cases of treatment-resistant ALL. Apart from Novartis, some other big pharmaceutical companies including Pfizer have entered the space. Juno Therapeutics, Takara Bio and Kite Pharma are other active players.

We anticipate the market to continue to rise steadily as several DC vaccines and CAR-T cell therapies get approval, both as monotherapy and combination therapy.

The 'Dendritic Cell and CAR-T Therapies Market, 2014-2024' report provides an extensive study on the two Whole Cell based Immunotherapies: Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor (CAR) T-cell Therapy. These upcoming fields of therapeutics are still in infancy, with only two DCT vaccines commercially available in 2014. The report covers various aspects, such as, existing cancer immunotherapeutics, main players in the DCT and CAR-T industry, products in clinical / pre-clinical research, technological developments and upcoming opportunities for several stakeholders.

As pharma companies continue to expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analysing:

  • DCT and CAR-T pipeline in terms of phase of development, target indications, types of molecule, etc.
  • Companies participating in the development of these products highlighting their product portfolio, financial performance, patents, recent collaborations and future outlook.
  • Interest of venture capital firms and recent funding rounds of small biotech firms developing whole cell based immunotherapies.
  • Competitive landscape and inherent threats to growth in the short and long term.
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.

The report gives an estimate of the short-mid term and long term markets for the period 2014 - 2024. The research, analysis and insights presented in this report include potential sales of the marketed DCT vaccine (PROVENGE) and eight pipeline products in late phases of development.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1.CreaVax-RCC (by JW CreaGene) became the first approved dendritic cell vaccine in 2007. However, its market has been restricted to South Korea. PROVENGE (by Dendreon) received FDA approval for launch in the US in 2010.
  • 2.In addition, we have identified 30 dendritic cell vaccines and 12 CAR-T therapies which are currently in clinical and preclinical development for different oncological indications. Of these, four dendritic cell vaccines are in Phase III trials. Majority of the CAR-T therapies are in early stages of development.
  • 3.The market is characterised by the presence of several small biotech firms; these firms are likely to benefit as more molecules reach advanced stages of development in the coming few years.
  • 4.There has been a growing interest from Venture Capital firms. In fact, in 2013 / 2014, several companies involved in DCT and CAR-T therapies have cumulatively raised over USD 500 million in venture funding rounds; this activity is likely to increase further and will help these companies drive their respective products to commercialisation.
  • 5.We expect dendritic cell and CAR-T therapies market to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualised rate of 29.8%.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. The summary offers an insight to key highlights of the whole cell based immunotherapies and where the market is headed in the mid-long term.

Chapter 3 provides a general introduction to the market. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and, specifically, the emergence DCT and CAR-T.

Chapter 4 provides a comprehensive landscape of the whole cell based immunotherapy market. This chapter includes information on over 40 molecules which are currently in different stages of development (both clinical and pre-clinical / discovery). The detailed analysis of this development pipeline includes information on therapy class, most commonly targeted indications and current phases of development.

Chapter 5 focuses on DCT and presents the current scenario and the future outlook of this specific class of vaccines. The chapter includes detailed profiles of marketed and late stage products. We have presented information on several parameters such as history of development, clinical trial results, manufacturing, cost and reimbursement. It includes the likely sales forecast of the drugs currently in Phase III or higher stage of development.

Chapter 6 focuses on CAR-T and presents the current scenario and the future outlook of this therapy. As with DCTs, this chapter provides a holistic view on the various cell therapy products belonging to CAR-Ts and their future sales potential.

Chapter 7 provides the detailed company profiles of the leading players in the market. Each company profile includes information on financial performance, geographical presence, marketed / pipeline drugs, recent collaborations and developments.

Chapter 8 is a collection of interview transcript(s)of the discussions which were held during the course of this study.

Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Cancer Therapeutics and Immuno-Oncology

  • 3.1. Chapter Overview
  • 3.2. The Four Pillars of Cancer Therapy
  • 3.3. Immunotherapy: Gaining A Strong Foothold
    • 3.3.1. Activation and Suppression Immunotherapies
  • 3.4. Immuno-Oncology (Cancer Immunotherapy)
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
    • 3.5.2. By Product Class
      • 3.5.2.1. Monoclonal Antibodies (mAbs)
      • 3.5.2.2. Cytokines
      • 3.5.2.3. Immune Checkpoint Inhibitors
      • 3.5.2.4. Cell Based Therapies

4. Current Market Landscape

  • 4.1. Scope and Observations
  • 4.2. First DCT Reached the Market in 2007
  • 4.3. Whole Cell Based Immunotherapies: Clinical and Preclinical Pipeline
    • 4.3.1. DCTs are More Popular; CAR-Ts are Emerging
    • 4.3.2. Four Products in Late Stage Clinical Development
  • 4.4. DCT and CAR-Ts: A Comparison
  • 4.5. DCT and CAR-Ts: Funding being Led by Venture Capital Firms
  • 4.6. Overall Future Outlook
    • 4.6.1. Scope and Forecast Methodology
    • 4.6.2. Overall Market Size and Forecast, 2014 - 2024

5. Dendritic Cell Therapy: Key Molecules and Future Outlook

  • 5.1. Introduction
  • 5.2. Two Approved Products in the Market
  • 5.3. Several Novel Molecules in the Pipeline
    • 5.3.1. Focus on Solid Tumors
    • 5.3.2. 50% of Molecules are in Phase II Clinical Trials and Above
    • 5.3.3. Development Being Led by Small Biotech Firms
    • 5.3.4. Gradual Evolution Towards Allogenic Dendritic Cells
  • 5.4. PROVENGE (Dendreon Corporation)
    • 5.4.1. Introduction
    • 5.4.2. Mechanism of Action
    • 5.4.3. Development Status
    • 5.4.4. Key Clinical Trial Results
    • 5.4.5. Manufacturing
    • 5.4.6. Treatment Cost and Reimbursement
    • 5.4.7. Historical Sales, 2010 - H1 2014
    • 5.4.8. Competition for PROVENGE
    • 5.4.9. PROVENGE Sales Forecast, 2014 - 2024
  • 5.5. CreaVax-RCC (JW CreaGene)
    • 5.5.1. Introduction
    • 5.5.2. Development Status
    • 5.5.3. Dosage, Treatment Cost and Manufacturing
  • 5.6. AGS-003 (Argos Therapeutics)
    • 5.6.1. Introduction
    • 5.6.2. Arcelis: The Underlying Technology
    • 5.6.3. Development Status
    • 5.6.4. Key Clinical Trial Results
    • 5.6.5. Dosage, Treatment Cost and Manufacturing
    • 5.6.6. Target Population
    • 5.6.7. Competition for AGS-003
    • 5.6.8. Collaborations
    • 5.6.9. AGS-003 Sales Forecast, 2014 - 2024
  • 5.7. DCVax-L (Northwest Biotherapeutics)
    • 5.7.1. Introduction
    • 5.7.2. Prevalence of Disease
    • 5.7.3. Mechanism of Action
    • 5.7.4. Development Status
    • 5.7.5. Dosage, Treatment Cost and Manufacturing
    • 5.7.6. DCVax-L Sales Forecast, 2014 - 2024
  • 5.8. DCVAC/PCa (SOTIO)
    • 5.8.1. Introduction
    • 5.8.2. Active Cellular Immunotherapy: The Underlying Technology
    • 5.8.3. Mechanism of Action
    • 5.8.4. Prevalence of Disease
    • 5.8.5. Development Status
    • 5.8.6. Dosage, Treatment Cost and Manufacturing
    • 5.8.7. DCVAC/PCa Sales Forecast, 2014 - 2024
  • 5.9. Eltrapuldencel-T (NeoStem)
    • 5.9.1. Introduction
    • 5.9.2. Prevalence of Disease
    • 5.9.3. Mechanism of Action
    • 5.9.4. Development Status
    • 5.9.5. Key Clinical Trial Results
    • 5.9.6. Dosage, Treatment Cost and Manufacturing
    • 5.9.7. Collaborations
    • 5.9.8. Competitive Analysis
    • 5.9.9. Eltrapuldencel-T Sales Forecast, 2014 - 2024
  • 5.10. Overall Dendritic Cell Therapy Market, 2014 - 2024
  • 5.11. Technological Developments
    • 5.11.1. Allogenic Dendritic Cell Derived Therapies
    • 5.11.2. Tolerogenic Dendritic Cells
  • 5.12. Dendritic Cell Therapy: Roots Analysis' Perspective

6. Chimeric Antigen Receptor-T Cell Therapy

  • 6.1. Introduction
  • 6.2. Structure of Chimeric Antigen Receptor
    • 6.2.1. History of Development
    • 6.2.2. No Marketed Product Yet; Novel Products in Pipeline
    • 6.2.3. Development Being Led by Small Biotech Firms
    • 6.2.4. CD19: The Most Sought After Target
    • 6.2.5. Companies Moving Beyond Haematological Malignancies
  • 6.3. CTL019 (Novartis)
    • 6.3.1. Introduction
    • 6.3.2. History of Development
    • 6.3.3. Prevalence of Disease
    • 6.3.4. Mechanism of Action
    • 6.3.5. Development Status
    • 6.3.6. Key Clinical Trial Results
    • 6.3.7. Dosage, Treatment Cost And Manufacturing
    • 6.3.8. Collaborations
    • 6.3.9. CTL019 Sales Forecast, 2014 - 2024
  • 6.4. JCAR (Juno Therapeutics)
    • 6.4.1. Introduction
    • 6.4.2. Mechanism of Action
    • 6.4.3. Development Status
    • 6.4.4. Key Clinical Trial Results
    • 6.4.5. Dosage, Treatment Cost and Manufacturing
    • 6.4.6. Collaborations
  • 6.5. KTE-C19 (Kite Pharma)
    • 6.5.1. Introduction
    • 6.5.2. Mechanism of Action
    • 6.5.3. Development Status
    • 6.5.4. Key Clinical Trial Results
    • 6.5.5. Dosage, Treatment Cost and Manufacturing
    • 6.5.6. Collaborations
    • 6.5.7. KTE-C19 Sales Forecast, 2014 - 2024
  • 6.6. CD19 CAR (Takara Bio)
    • 6.6.1. Introduction
    • 6.6.2. Mechanism of Action
    • 6.6.3. Development Status
    • 6.6.4. Dosage, Treatment Cost and Manufacturing
    • 6.6.5. Collaborations
    • 6.6.6. CD19 CAR Sales Forecast, 2014 - 2024
  • 6.7. EFGRvIII CAR (Kite Pharma)
    • 6.7.1. Introduction
    • 6.7.2. Mechanism of Action
    • 6.7.3. Development Status
    • 6.7.4. Dosage, Treatment Cost and Manufacturing Details
    • 6.7.5. Collaborations
    • 6.7.6. EGFRVIII CAR Sales Forecast, 2014 - 2024
  • 6.8. ANTI-GD2 CAR (Bellicum Pharmaceuticals)
    • 6.8.1. Introduction
    • 6.8.2. Mechanism of Action
    • 6.8.3. Development Status
    • 6.8.4. Dosage
    • 6.8.5. Collaborations
  • 6.9. Overall CAR-T Therapy Market, 2014 - 2024
  • 6.10. Technological Developments
    • 6.10.1. Use of Safety Switch to Increase Safety
    • 6.10.2. Use of Allogenic Sources
  • 6.11. CAR-T Therapy: Roots Analysis' Perspective

7. Company Profiles

  • 7.1. Overview
  • 7.2. Dendreon Corporation
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Product Portfolio
    • 7.2.4. Patent Portfolio
    • 7.2.5. Partnerships
    • 7.2.6. Future Outlook
  • 7.3. JW CreaGene
    • 7.3.1. Company Overview
    • 7.3.2. Product Portfolio
    • 7.3.3. Patent Portfolio
    • 7.3.4. Partnerships
    • 7.3.5. Future Outlook
  • 7.4. Northwest Biotherapeutics
    • 7.4.1. Company Overview
    • 7.4.2. Financial Information
    • 7.4.3. Product Portfolio
    • 7.4.4. Patent Portfolio
    • 7.4.5. Partnerships
    • 7.4.6. Funding
    • 7.4.7. Future Outlook
  • 7.5. Argos Therapeutics
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Product Portfolio
    • 7.5.4. Patent Portfolio
    • 7.5.5. Partnerships
    • 7.5.6. Manufacturing
    • 7.5.7. Funding
    • 7.5.8. Future Outlook
  • 7.6. NeoStem
    • 7.6.1. Company Overview
    • 7.6.2. Financial Information
    • 7.6.3. Product Portfolio
    • 7.6.4. Partnerships
    • 7.6.5. Manufacturing
    • 7.6.6. Future Outlook
  • 7.7. SOTIO
    • 7.7.1. Company Overview
    • 7.7.2. Financial Information
    • 7.7.3. Product Portfolio
    • 7.7.4. Patent Portfolio
    • 7.7.5. Partnerships
    • 7.7.6. Manufacturing Facilities
  • 7.8. Novartis
    • 7.8.1. Company Overview
    • 7.8.2. Financial Information
    • 7.8.3. Product Portfolio
    • 7.8.4. Partnerships
    • 7.8.5. Manufacturing
    • 7.8.6. Future Outlook
  • 7.9. Juno Therapeutics
    • 7.9.1. Company Overview
    • 7.9.2. Financial Information
    • 7.9.3. Product Portfolio
    • 7.9.4. Patent Portfolio
    • 7.9.5. Partnerships
    • 7.9.6. Future Outlook
  • 7.10. Kite Pharma
    • 7.10.1. Company Overview
    • 7.10.2. Financial Information
    • 7.10.3. Product Portfolio
    • 7.10.4. Partnerships
    • 7.10.5. Future Outlook
  • 7.11. Takara Bio
    • 7.11.1. Company Overview
    • 7.11.2. Financial Overview
    • 7.11.3. Product Portfolio
    • 7.11.4. Partnerships
    • 7.11.5. Manufacturing
    • 7.11.6. Future Outlook
  • 7.12. Other Companies
    • 7.12.1. Asterias Biotherapeutics
      • 7.12.1.1. Stem cell and Regenerative Medicine Platform
      • 7.12.1.2. DCT Pipeline
      • 7.12.1.3. Partnerships
    • 7.12.2. Bellicum Pharmaceuticals
      • 7.12.2.1. CaspaCIDe Technology (Cell Elimination)
      • 7.12.2.2. DeCIDe Technology (Cell Activation) / DCT Pipeline
    • 7.12.3. Cellular Biomedicine Group
      • 7.12.3.1. Regenerative Medicine and Cell Therapy
      • 7.12.3.2. DCT Pipeline
      • 7.12.3.3. Patent Portfolio
    • 7.12.4. DCPrime BV
      • 7.12.4.1. DCOne Platform
      • 7.12.4.2. DCT Pipeline
      • 7.12.4.3. Partnerships
    • 7.12.5. Immunicum
      • 7.12.5.1. COMBIG Platform /DCT Pipeline
      • 7.12.5.2. CD70 Platform
      • 7.12.5.3. Patent Portfolio
    • 7.12.6. Kiromic
      • 7.12.6.1. DCT Pipeline
      • 7.12.6.2. Other Therapeutic and Diagnostic Technologies
    • 7.12.7. MediGene
      • 7.12.7.1. DCT Pipeline
      • 7.12.7.2. T cell Immunotherapy Platform
      • 7.12.7.3. Patent Portfolio
      • 7.12.7.4. Partnerships
    • 7.12.8. Prima BioMed
      • 7.12.8.1. DCT Pipeline
      • 7.12.8.2. Partnerships
    • 7.12.9. bluebird bio
      • 7.12.9.1. Gene Therapy Platform
      • 7.12.9.2. CAR-T Pipeline
      • 7.12.9.3. Partnerships
    • 7.12.10. Cellectis
      • 7.12.10.1. UCART Technology
      • 7.12.10.2. CAR-T Pipeline

8. Interview Transcripts

9. Conclusion

  • 9.1. Whole Cell Based Therapy: Expanding the Cancer Immunotherapeutics Market
  • 9.2. The Emerging Market Reveals a Promising Future
  • 9.3. Companies are Focussing on Development of In-house Technology/Platform
  • 9.4. With A Healthy Growth Rate, We Expect It To Be A Multi Billion Market
  • 9.5. Concluding Remarks

10. Appendix 1: Tabulated Data

11. Appendix 2: List of Companies and Organisations

List of Figures

  • Figure 2.1 DCT and CAR-T Clinical Trials: Market Map
  • Figure 3.1 Four Pillars of Cancer Therapy
  • Figure 3.2 Passive and Active Cancer Immunotherapies
  • Figure 4.1 Pipeline Analysis: Distribution by Type of Molecule
  • Figure 4.2 Pipeline Analysis: Distribution by Highest Phase of Development
  • Figure 4.3 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Figure 5.1 DCT Pipeline Analysis: Distribution of Molecules by Indication
  • Figure 5.2 DCT Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
  • Figure 5.3 DCT Pipeline Analysis: Distribution of Molecules by Company
  • Figure 5.4 DCT Pipeline Analysis: Sources of Dendritic Cells
  • Figure 5.5 PROVENGE Sales, 2010 - H1 2014 (USD Million)
  • Figure 5.6 PROVENGE: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 5.7 AGS-003: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 5.8 DCVax-L: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 5.9 DCVAC/PCa: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 5.10 Geographical Distribution of Death Rate due to Skin Cancer (Cases per 100,000 Persons)
  • Figure 5.11 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 5.12 Overall DCT Forecast, 2014-2024 (USD Million)
  • Figure 5.13 Overall DCT Forecast (2014, 2019, 2024): Distribution by Vaccines
  • Figure 5.14 Drivers and Restraints of DCT
  • Figure 6.1 Development of CAR-T Cells
  • Figure 6.2 CAR-T Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
  • Figure 6.3 CAR-T Pipeline Analysis: Distribution of Molecules by Company
  • Figure 6.4 CAR-T Pipeline Analysis: Distribution by Target
  • Figure 6.5 Incidence of Four Main Types of Leukaemia in the US, 2013 (%)
  • Figure 6.6 CTL019: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 6.7 KTE-C19: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 6.8 CD19 CAR: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Figure 6.9 EGFRVIII CAR: Sales Forecast 2014 - 2024: Base Scenario (USD Million)
  • Figure 6.10 Overall CAR-T Forecast, 2014-2024 (USD Million)
  • Figure 6.11 Overall CAR-T Forecast (2017, 2021, 2024): Distribution by Therapy
  • Figure 6.12 Drivers and Restraints of CAR-T Therapy
  • Figure 7.1 Dendreon Corporation: Revenues (USD Million), 2010-H1 2014
  • Figure 7.2 Northwest Biotherapeutics: Revenues (USD), 2003-2013
  • Figure 7.3 Argos Therapeutics: Revenues, 2011-2013 (USD Million)
  • Figure 7.4 NeoStem: Revenues, 2012- 2013 (USD Million)
  • Figure 7.5 PPF Group: Revenues, 2010-2013 (EUR Million)
  • Figure 7.6 Novartis Healthcare: Revenue, 2013: Distribution by Operating Segments (USD Million)
  • Figure 7.7 Novartis Pharmaceuticals: Revenues, 2009-2013 (USD Million)
  • Figure 7.8 Takara Bio: Revenue, 2010-2014 (YEN Million)
  • Figure 7.9 Takara Bio: Revenue, 2014: Distribution by Operating Segments (YEN Million)
  • Figure 9.1 Whole Cell Therapy Market (USD Million), 2017, 2021 and 2024

List of Tables

  • Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
  • Table 4.1 DCT and CAR-Ts: Clinical and Preclinical Pipeline
  • Table 4.2 Comparison of DCT and CAR-Ts
  • Table 4.3 DCT and CAR-T Companies: Funding Rounds
  • Table 4.4 Whole Cell based Therapy: Current Development Phase and Expected Launch Years
  • Table 5.1 DCT: Clinical and Preclinical Pipeline
  • Table 5.2 PROVENGE: Current Status of Development
  • Table 5.3 Comparison of Recently Approved Drugs for mCRPC
  • Table 5.4 Advantages of PROVENGE Over Competitors
  • Table 5.5 CreaVax-RCC: Current Status of Development
  • Table 5.6 AGS-003: Current Status of Development
  • Table 5.7 Target Population for AGS-003 in the US, 2013
  • Table 5.8 Comparison of Drugs Approved for RCC
  • Table 5.9 AGS-003: Partnerships
  • Table 5.10 DCVax-L: Current Status of Development
  • Table 5.11 DCVAC/PCa: Current Status of Development
  • Table 5.12 Eltrapuldencel-T: Current Status of Development
  • Table 5.13 Comparison of Marketed Targeted Therapeutics for Melanoma
  • Table 5.14 Advantages of Eltrapuldencel-T
  • Table 5.15 DCT Forecast: Expected Launch Years
  • Table 6.1 CAR-T Therapy: Clinical and Preclinical Pipeline
  • Table 6.2 CTL019: Current Status of Development
  • Table 6.3 JCAR: Current Status of Development
  • Table 6.4 KTE-C19: Current Status of Development
  • Table 6.5 CD19 CAR: Current Status of Development
  • Table 6.6 EGFRvIII CAR-T: Current Status of Development
  • Table 6.7 Anti-GD 2-CAR: Current Status of Development
  • Table 6.8 CAR-T Forecast: Expected Launch Years
  • Table 7.1 Dendreon Corporation: Patent Portfolio
  • Table 7.2 JW CreaGene: Product Portfolio
  • Table 7.3 JW CreaGene: Patent Portfolio
  • Table 7.4 Northwest Biotherapeutics: Product Portfolio
  • Table 7.5 Northwest Biotherapeutics: Patent Portfolio
  • Table 7.6 AGS-003: Development Status
  • Table 7.7 Argos Therapeutics: Patent Portfolio
  • Table 7.8 Developmental status of DCVAC
  • Table 7.9 SOTIO: Patent Portfolio
  • Table 7.10 Asterias Biotherapeutics: DCT Pipeline, 2014
  • Table 7.11 Bellicum Pharmaceutical: DCT Pipeline, 2014
  • Table 7.12 CBMG: DCT Pipeline, 2014
  • Table 7.13 DCPrime: DCT Pipeline, 2014
  • Table 7.14 Immunicum: DCT Pipeline, 2014
  • Table 7.15 Kiromic: DCT Pipeline, 2014
  • Table 7.16 MediGene: DCT Pipeline, 2014
  • Table 7.17 PrimaBioMed: DCT Pipeline, 2014
  • Table 7.18 bluebird bio:CAR-T Pipeline, 2014
  • Table 7.19 Cellectis: CAR-T Pipeline, 2014
  • Table 10.1 Pipeline Analysis: Distribution by Type of Molecule
  • Table 10.2 Pipeline Analysis: Distribution by Highest Phase of Development
  • Table 10.3 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.4 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
  • Table 10.5 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Conservative Scenario (USD Million)
  • Table 10.6 Pipeline Analysis: Distribution of Molecules by Indication
  • Table 10.7 Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
  • Table 10.8 Pipeline Analysis: Distribution of Molecules by Company
  • Table 10.10 Pipeline Analysis: Sources of Dendritic Cells
  • Table 10.11 PROVENGE Sales, 2010 - H1 2014 (USD Million)
  • Table 10.12 PROVENGE: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.13 PROVENGE: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.14 PROVENGE: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.15 AGS-003: Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.16 AGS-003: Sales Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
  • Table 10.17 AGS-003: Sales Forecast, 2014 - 2024: Conservative Scenario (USD Million)
  • Table 10.18 DCVax-L: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.19 DCVax-L: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.20 DCVax-L: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.21 DCVAC/PCa: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.22 DCVAC/PCa: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.23 DCVAC/PCa: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.24 Geographical Distribution of Death Rate due to Skin Cancer (Cases per 100,000 Persons)
  • Table 10.25 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.26 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.27 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.28 Overall DCT Forecast, 2014-2024 (USD Million)
  • Table 10.29 Overall DCT Forecast, 2014, 2019, 2024: Distribution by Vaccine
  • Table 10.30 CAR-T Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
  • Table 10.31 CAR-T Pipeline Analysis: Distribution of Molecules by Company
  • Table 10.32 CAR-T Pipeline Analysis: Distribution by Target
  • Table 10.33 Incidence of Four Main Types of Leukaemia in the US, 2013 (%)
  • Table 10.34 CTL019: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.35 CTL019: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.36 CTL019: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.37 KTE-C19: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.38 KTE-C19: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.39 KTE-C19: Sales Forecast, 2014 -2024, Conservative Scenario (USD Million)
  • Table 10.40 CD19 CAR: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
  • Table 10.41 CD19 CAR: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.42 CD19 CAR: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.43 EGFRVIII CAR: Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.44 EGFRVIII CAR: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
  • Table 10.45 EGFRVIII CAR: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
  • Table 10.46 Overall CAR-T Forecast, 2014-2024 (USD Million)
  • Table 10.47 Overall CAR-T Forecast, 2017, 2021, 2024: Distribution by Molecule
  • Table 10.48 Dendreon Corporation: Revenues (USD Million), 2010-H1 2014
  • Table 10.49 Northwest Biotherapeutics: Revenues (USD), 2003-2013
  • Table 10.50 Argos Therapeutics: Annual Revenues, 2011-2013 (USD Million)
  • Table 10.51 NeoStem: Annual Revenues 2012- 2013 (USD Million)
  • Table 10.52 PPF Group: Annual Revenues 2010-2013 (EUR Million)
  • Table 10.53 Novartis Healthcare: Distribution by Operating Segments, 2013 (USD Million)
  • Table 10.54 Novartis Pharmaceuticals: Annual Revenues, 2009-2013 (USD Million)
  • Table 10.55 Takara Bio: Annual Revenue, 2010-2014 (YEN Million)
  • Table 10.56 Takara Bio: Revenue Distribution by Operating Segment, 2014 (YEN Million)
  • Table 10.57 Whole Cell Therapy Market 2017, 2021 and 2024 (USD Billion)

Listed Companies

The following companies and organisations have been mentioned in this report.

  • 1. Activartis Biotech
  • 2. Argos Therapeutics
  • 3. Artecel
  • 4. Asterias Biotherapeutics
  • 5. Bayer Healthcare
  • 6. Bellicum Pharmaceuticals
  • 7. bluebird bio
  • 8. BMS
  • 9. Cabaret Biotech Limited
  • 10. California Stem Cell, Inc.
  • 11. Cancer Research UK
  • 12. Cancer Research Technology
  • 13. Celdara Medical
  • 14. Celgene Corporation
  • 15. Cellectis
  • 16. Cellular Biomedicine Group
  • 17. Centre Memorial Sloan- Kettering Cancer
  • 18. Ciba-Geigy
  • 19. City of Hope Medical Center
  • 20. Cognate
  • 21. DanDrit Biotech
  • 22. DCPrime
  • 23. Delta-Vir Immunotherapeutics
  • 24. Dendreon
  • 25. Duke University
  • 26. Fraunhofer Institute
  • 27. Fred Hutchinson Cancer Research Center
  • 28. Fujifilm Diosynth Biotechnologies
  • 29. Genentech
  • 30. Genetix Pharmaceuticals
  • 31. German Research Foundation
  • 32. Geron
  • 33. GlaxoSmithKline
  • 34. Green Cross Corporation
  • 35. Horizon Technology Finance
  • 36. Immunicum
  • 37. ImmunoCellular Therapeutics
  • 38. Jichi Medical University Hospital
  • 39. Johnson and Johnson
  • 40. Juno Therapeutics
  • 41. JW CreaGene
  • 42. Kings College
  • 43. Kiromic
  • 44. Kitasato Institute
  • 45. Kite Pharma
  • 46. Masonic Cancer Center
  • 47. Medical School of Charles
  • 48. MediGene
  • 49. Medinet
  • 50. Memorial Sloan Kettering Cancer Centre
  • 51. Merck
  • 52. National Cancer Institute
  • 53. NeoStem
  • 54. Northwest Biotherapeutics
  • 55. Novartis
  • 56. Onyx Pharmaceuticals
  • 57. OriBase Pharma
  • 58. Orpechem Peptide Chemicals
  • 59. Oxford BioMedica
  • 60. Paul Ehrlich Institute
  • 61. Pfizer
  • 62. PharmaCell
  • 63. Pharmstandard International
  • 64. PPF Group
  • 65. Prima BioMed
  • 66. Progenitor Cell Therapy LLC
  • 67. Regen BioPharma
  • 68. Roche
  • 69. Rockefeller University
  • 70. Sandoz
  • 71. Seattle Children's Hospital
  • 72. Signifix
  • 73. SOTIO
  • 74. Takara Bio
  • 75. Technological Developments
  • 76. Tella
  • 77. TILT Biotherapeutics
  • 78. Trianta Immunotherapies
  • 79. University of Pennsylvania
  • 80. University of Wisconsin
  • 81. University of Antwerp
  • 82. University of Gent
  • 83. Vlaams Instituutvoor Biotechnologie
  • 84. VU University Medical Center
Back to Top